Mesoblast appoints new director
Mesoblast (ASX:MSB) has appointed former Roche Pharmaceuticals CEO William M Burns to its board as a non-executive director.
Burns was CEO of the Roche division from 2005-2009 and also served as a non-executive director on the Roche board between 2010 and this year.
He also serves on the board of Genentech, Chugai Pharmaceutical and Shire.
“Regenerative medicine has the potential to make a major impact on the way serious medical diseases are treated,” Burns commented. “Mesoblast is the global leader in the development of adult stem cell therapies and I am delighted to join this exciting company.”
Mesoblast recently reported its results for the first half of FY14, revealing it ended the period with a cash balance of $250.3 million despite an 11% higher net loss of $30.8 million.
Last month, the company secured a European patent covering use of its mesenchymal precursor cells (MPCs) in cardiac and vascular conditions.
Mesoblast (ASX:MSB) shares were trading 1.04% higher at $5.81 as of around 1.30 pm on Monday.
Prenatal stress leaves a molecular mark on newborns
An international study has uncovered how stress experienced during pregnancy can affect newborns...
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
